Please assess the completion status of the following clinical trial:

Trial Title: Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmation of renal cell carcinoma with a clear cell histologic component~2. Patients must present with stage IV disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent.~3. Measurable disease according to RECIST criteria are required but patients with evaluable lesions without measurable lesions are allowed to be enrolled to this study~4. ECOG performance status 2 or better~5. Age 18 years or older~6. Adequate bone marrow, hepatic, and renal function~7. Life expectancy of \> 3 months~8. Singed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment~Exclusion Criteria:~1. Known spinal cord compression or carcinomatous meningitis~2. Diagnosis of any serious secondary malignancy within the last 2 years, except for adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma of cervix uteri~3. Hypertension that cannot be controlled by medications (blood pressure \> 150/90 mmHg despite optimal medical therapy)~4. Treatment with anticonvulsant agents and treatment with therapeutic doses of coumadin currently or within 2 weeks prior to first day of sunitinib administration. Low dose coumadin for DVT prophylaxis is permitted (up to 2 mg/day).~5. Pregnancy or breast feeding.~6. Other severe acute or chronic medical or psychiatric condition~7. Prior treatment on sunitinib, sorafenib, or bevacizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sunitinib 4/2 (Type: ACTIVE_COMPARATOR): Sunitinib 50 mg PO 4-week on and 2-week off
- Sunitinib 2/1 (Type: EXPERIMENTAL): Sunitinib 50 mg PO 2-week on 1-week off

Based on this trial design, predict the completion outcome and termination type (if applicable).